Aurobindo Pharma has informed that it has enclosed a copy of the Press Release on 9th December 2020 that is being issued by the Company in connection with USFDA approval received by the Company for Dexmedetomidine HCL in 0.9% Sodium Chloride Injection.
The above information is a part of company’s filings submitted to BSE.